Agents Used in Antiretroviral Therapy

  • Authors: Philip Grant, MD (More Info)
  • Editors in Chief: Daniel R. Kuritzkes, MD; Joseph J. Eron, Jr., MD
  • Last Reviewed: 4/9/19 (What's New)

Summary

  • Nevirapine is an NNRTI indicated in combination with other antiretroviral agents
  • It can be administered to treatment-naive and treatment-experienced patients, but caution should be employed when initiating nevirapine-based antiretroviral therapy in women with CD4+ cell counts > 250 cells/mm3 or men with CD4+ cell counts > 400 cells/mm3
  • Nevirapine should be administered initially at 200 mg once daily (immediate-release formulation) for 14 days; if well tolerated, full dose is 200 mg twice daily (immediate-release) or 400 mg once daily (extended-release)[FDA Nevirapine XR]

    Action required

    Keywords: Hepatic Complications, Initial Antiretroviral Therapy, Management of Treatment-Experienced Patients, Resource-Limited Settings, Special Populations, Treatment Complications

    ©2018 Clinical Care Options, LLC. All Rights Reserved.

    The materials published via inPractice® reflect the views of the reviewers or authors of the material, not those of Clinical Care Options, LLC, the accredited provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.